stent

It has been suggested that Stent Graft be merged into this article or section. (Discuss)

Endoscopic image of self-expanding metallic stent in esophagus, which was used to palliatively treat esophageal cancer.

Endoscopic image of biliary stent seen protruding from ampulla of Vater at the time of duodenoscopy

In medicine, a stent is a tube that is inserted into a natural conduit of the body to prevent or counteract a disease-induced localized flow constriction.

Applications

The main purpose of a stent is to counteract significant decreases in vessel or duct diameter by acutely propping open the conduit by a mechanical scaffold or stent. Stents are often used to alleviate diminished blood flow to organs and extremities beyond an obstruction in order to maintain an adequate delivery of oxygenated blood. Although the most common use of stents is in coronary arteries, they are widely used in other natural body conduits, such as central and peripheral arteries and veins, bile ducts, esophagus, colon, trachea or large bronchi, ureters, and urethra.

Etymology

The origin of the word stent remains unsettled. The verb stenting was used for centuries for the process of stiffening garments (a usage long obsolete, per the OED) and some believe this to be the origin. Others attribute the noun stent to Jan F. Esser, a Dutch plastic surgeon who in 1916 used the word to describe a dental impression compound invented in 1856 by the English dentist Charles Stent (1807–1885), which Esser employed to craft a form for facial reconstruction. The full account is described in the Journal of the History of Dentistry. [1] According to the author, from the use of Stent's compound as support for facial tissues grew the eventual use of stent to open various bodily structures. Worth noting though is that the first "stents" used in medical practice were initially called "Wallstents".

Types of stent

Vascular

• Bare Metal Stent
• Covered Stent and Stent Graft
• Drug-eluting stent

- Therapy: Stent implantation versus Coronary bypass surgery Coronary heart disease (CHD) is a major cause of morbidity and mortality throughout the world, and both surgical revascularisation (coronary artery bypass grafting, CABG) and percutaneous coronary intervention (PCI) are established treatment options. The rapid developments in both surgical and percutaneous techniques have been such that the choice of the optimum revascularisation strategy is changing, often without an established evidence base; this is particularly true in complex conditions including patients with three-vessel and left main stem anatomy. The widespread use of drug eluting stents has resulted in a significant reduction in patients referred for CABG although published data favours the surgical approach in this high-risk group.

• The SYNTAX Trial^[1] aims to explore the interface between treatment with CABG and PCI in patients with three-vessel and left main stem disease, comparing CABG using contemporary techniques and PCI using drug eluting TAXUS stents. The aim of the trial is to establish non-inferiority of PCI with CABG. The unique feature of the SYNTAX trial is the ‘all comers’ strategy. A team comprising a cardiac surgeon and an interventional cardiologist assesses each patient; if equivalent revascularisation is applicable using both techniques, the patient is accepted for randomization; if either CABG or PCI is deemed unsuitable for technical reasons or the presence of co-morbidities, then the patient is recruited into one of two parallel registries which will track these patients undergoing either CABG or PCI. The patient will not be included in the randomized cohort. 1800 patients will be randomized (1:1) between CABG and PCI. The primary end-point is a major adverse, cardiac and cerbrovascular event at one year. All patients will be followed for five years. Of the 1800 patients, 710 with left main stem disease will be randomized between CABG and PCI. In this sub-group, repeat cardiac catheterisation will be undertaken after the one-year primary endpoint to determine graft and native vessel patency (the Le Mans sub-study).

• The SYNTAX Trial is one of the most important trials ever undertaken in the field of coronary revascularisation and will provide a rational basis for choosing the optimum revascularisation strategy in patients for many years to come.

- Problems: One of the drawbacks of vascular stents is the potential development of a thick smooth muscle tissue inside the lumen, the so-called neointima. Development of a neointima is variable but can at times be so severe as to re-occlude the vessel lumen (restenosis), especially in the case of smaller diameter vessels, which often results in reintervention. Consequently, current research focuses on the reduction of neointima after stent placement. Considerable improvements have been made, including the use of more bio-compatible materials, anti-inflammatory drug-eluting stents, resorbable stents, and others. Fortunately, even if stents are eventually covered by neointima, the minimally invasive nature of their deployment makes reintervention possible and usually straightforward.

• On September 4, 2007, an international study showed that some heart attack patients would be better off without using drug-coated stents in emergency to open their clogged arteries (patients were 5 times more likely to die after 2 years than those who received metal stents). Dr. Valentin Fuster, director of the Cardiovascular Institute at Mount Sinai School of Medicine in New York said stents are less commonly used in Europe, implanted in only about 15 % of patients there while drug-lined stents are used in up to 30% of Americans having heart attacks. The new research was presented by Dr. Gabriel Steg, of the Hospital Bichat-Claude Bernard in Paris, at a meeting of the European Society of Cardiology in Vienna (funded by Sanofi-Aventis). Dr. Eckhart Fleck, director of cardiology at the German Heart Institute in Berlin and a spokesman for the European Society of Cardiology said that "Drug-eluting stents are not for everyone." ^[2]

Urinary Tract

• Urethral/Prostatic Stents

- A urethral/prostatic stent might be needed if a man is unable to urinate. Often this situation occurs when an enlarged prostate pushes against the urethra, blocking the flow of urine. The placement of a stent can open the obstruction, allowing volitional voiding.

- In the U.S., there are currently only two FDA approved urethral stents: a temporary use stent, The Spanner^TM by AbbeyMoor Medical, Inc. [2]; and a permanent stent, The Urolume^TM by American Medical Systems.

• Ureteral Stents

Other

• CHD Stent
• Rectal Stent
• Oesophageal Stent
• Biliary Stent
• Pancreatic Stent

See also

• Angioplasty
• Bronchoscopy
• Colonoscopy
• Esophagogastroduodenoscopy
• Grommet
• Restenosis

References

1. ^ ClinicalTrials.gov NCT00114972
2. ^ Yahoo.com, International study shows stent risks

External links

Wikimedia Commons has media related to:

Stent

• Drug-Eluting Stents — Angioplasty.Org
• Cardiovascular and Interventional Radiological Society of Europe
• How a Dentist's Name Became a Synonym for a Life-saving Device: The Story of Dr. Charles Stent Journal of the History of Dentistry/Vol. 49, No. 2/July 2001

Donate to Wikimedia